Sequana Medical - Publication of additional data from POSEIDON study
Sequana Medical published additional data from its North-American PhIII study POSEIDON. Efficacy was confirmed, safety is in line with expectations, quality of life was statistically significantly improved and one year survival rate (70%) compares favorably to literature (50%). PMA still on track to be submitted in H2 23 with FDA approval foreseen in H2 24. This additional data further support the benefits of the alfapump and reinforce our confidence in its ability to replace current standard of care. No impact on valuation. As a reminder, based on the positive top-line data published in October 2022, we already allocate a 90%Sequana Medical NV. Sequana Medical NV is a Belgium-based company, which manufactures medical devices. The Company focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.